The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | Brentuximab vedotin for CTCL
Christoph Blazejak, MD, Department of Dermatology HELIOS Klinikum Krefeld, Krefeld, Germany, outlines the use of the CD30-targeting antibody-drug conjugate brentuximab vedotin in the treatment of cutaneous T-cell lymphoma (CTCL), highlighting a response rate of around 60% and a median progression-free survival of around a year. Dr Blazejak also comments on the safety profile of brentuximab vedotin and on the impact of its approval on the CTCL treatment landscape. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
